Unseparated or Ficoll-Hypaque (Pharmacia, Piscataway, NJ)-fractionated human cord blood cells were transplanted into sublethally irradiated severe combined immunodeficient (SCID) mice. High levels of multilineage engraftment, including myeloid and lymphoid lineages, were obtained with 80% of the donor samples as assessed by DNA analysis, fluorescence-activated cell sorting (FACS), and morphology. In contrast to previous and concurrent studies with adult human bone marrow (BM), treatment with human cytokines was not required to establish high-level human cell engraftment, suggesting that neonatal cells either respond dfferently to the murine microenvironment or they provide their own cytokines in a paracrine fashion. Committed and multipotential myelo-erythroid progenitors were detected HE MAJORITY OF CELLS within the hematopoietic system are mature cells that have a limited life span and need to be continuously replenished from immature progenitors. Ultimately, the entire hematopoietic system is derived from a small pool of stem cells that have extensive proliferative and differentiation capacity and give rise to all myeloid and lymphoid lineages. Stem cells also have extensive ability to self-renew and are able to engraft recipients for long periods of time after transplantation.' In the mouse, stem cells are best assayed by long-term repopulation of lethally irradiated recipients.' Insight into the biology of human stem cells has been hampered by the absence of experimental in vivo models. Several approaches have now been developed to establish in vivo models for human hematopoiesis by transplanting human bone marrow (BM) cells into immune-deficient mice.'-5 We have recently found that human growth factors significantly enhance the level of human cell proliferation in transplanted severe combined immunodeficient (SCID) mice and result in multilineage hematopoies k 6 SCID mice transplanted with human BM cells without growth factor injections had only low levels (less than 1%) of human cells in the marrow, whereas growth factor-treated mice showed much higher levels of human hematopoiesis (greater than 10%). Human cells engrafted in the marrow of untreated mice remained responsive to human growth factors even if treatment was delayed for up to 3 months indicating that immature human cells home to the mouse BM, where they can be maintained by the murine microenvironment.6
HE MAJORITY OF CELLS within the hematopoietic system are mature cells that have a limited life span and need to be continuously replenished from immature progenitors. Ultimately, the entire hematopoietic system is derived from a small pool of stem cells that have extensive proliferative and differentiation capacity and give rise to all myeloid and lymphoid lineages. Stem cells also have extensive ability to self-renew and are able to engraft recipients for long periods of time after transplantation.' In the mouse, stem cells are best assayed by long-term repopulation of lethally irradiated recipients.' Insight into the biology of human stem cells has been hampered by the absence of experimental in vivo models. Several approaches have now been developed to establish in vivo models for human hematopoiesis by transplanting human bone marrow (BM) cells into immune-deficient mice.'-5 We have recently found that human growth factors significantly enhance the level of human cell proliferation in transplanted severe combined immunodeficient (SCID) mice and result in multilineage hematopoies k 6 SCID mice transplanted with human BM cells without growth factor injections had only low levels (less than 1%) of human cells in the marrow, whereas growth factor-treated mice showed much higher levels of human hematopoiesis (greater than 10%). Human cells engrafted in the marrow of untreated mice remained responsive to human growth factors even if treatment was delayed for up to 3 months indicating that immature human cells home to the mouse BM, where they can be maintained by the murine microenvironment. 6 An alternative source of human hematopoietic stem cells is cord blood. In vitro studies have shown that cord blood contains large numbers of hematopoietic some of which have a high proliferative and replating potential compared with progenitors in adult BM.'"* Comparison of highly purified CD34+CD45RA1OCD71" candidate stem cells from human fetal liver, cord blood, and adult BM also showed a much higher in vitro proliferative potential of cord blood hematopoietic cells as compared with adult BM cells, whereas the highest proliferation was found in fetal liver cells." In addition, cord blood long-term culture-initiating cells (LTC-IC) could be maintained in vitro for significantly longer periods of time than adult BM LTC-IC.I4 These data suggest that cord blood hematopoietic cells are developmentally earlier than hematopoietic cells in adult BM. Based on the in vitro data suggesting the presence of large numbers of stem cells, cord blood has been used successfully for transplantation in pediatric patients.""' Because of the clinical implications, there is need to develop an experimental system to study the biology of these immature cord blood progenitor/stem cells. We report here the establishment of cord blood-derived hematopoiesis in SCID mice using a protocol similar to the one developed for transplanting adult BM into SCID mice: Stable human long-term hematopoiesis in transplanted mice was observed for at least 14 weeks indicating the engraftment of an early hematopoietic progenitor cell. Interestingly, human growth factors were not required to establish high levels of human hematopoiesis in cord blood-transplanted SCID mice. 
MATERIALS AND METHODS

Cord blood samples.
Cord blood samples were obtained from umbilical and placental tissues scheduled for discard as described according to procedures approved by our Institutional Review Boards.'" Cells were either left unseparated or low-density (less than 1.077 g/mL) cells were. collected after separation on Ficoll-Hypaque and a fusion protein of human interleukin-3 (huL3)human granulocyte-macrophage colony-stimulating factor (huGM-CSF) (PIXY321) (provided by D. Williams, Immunex Corp. Seattle, WA) every other day as intraperitoneal (IP) injections at a concentration of 10 pg and 6.8 pg per mouse, respectively. If not indicated otherwise, the mice were killed 4 weeks after transplantation.
DNA analysis. High molecular weight DNA was obtained from BM and other murine tissues by phenol extraction using standard protocols. DNA (5 pg) was digested with EcoR1, run on a 0.6% agarose gel, blotted onto a nylon membrane and hybridized with a human chromosome 17-specific a-satellite probe (pI7H8):' To quantify the presence of human cells in various tissues, the intensity of the characteristic 2.7-kb band in the samples was compared with humadmouse mixtures (0,O.l. 1.0, IO, 50, and 100% human DNA) as previously described! Multiple exposures of the autoradiographs were taken to ensure sensitivity down to 0.01% human DNA.
Flow cytometry. Two-or three-color flow cytometry was performed on a FACScan (Becton Dickinson, Mountain View, CA) as described!.** For erythrocyte lysis, mouse and human BM samples were diluted with 14 Hematopoietic progenitor assay. Semisolid cultures were performed as previously described? Briefly, 0.5 to 2 X I d cells mixed with IMDM were plated in 0.9% methylcellulose, 15% FCS, 15% pretested human plasma, 5 X lo-' m o m 2-mercaptoethano1,50 ngl mL huMGF, 5 nglmL PIXY321, 10 UlmL huIL-3.9 UlmL huGM-CSF, and 2 UlmL human erythropoietin. The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO2. After 10 to 14 days, the plates were scored for macrophage colony-forming unit (CFU-M), granulocyte-macrophage colony-forming unit (CFU-GM), granulocyte colony-forming unit (CFU-G), erythroid burstforming unit (BFU-E) and multilineage colony-forming unit (CFU-GEMM) by morphologic criteria and cytologic staining of selected colonies. These conditions are specific for the growth of human colonies as has been shown by different methods including morphol- For ogy, chromosome analysis, determination of hemoglobin isoforms, polymerase chain reaction, and plating of artificial mixtures of human and mouse BM6 (and data not shown). The specificity of these conditions was also independently confirmed by plating of BM cells from selected mice in Indianapolis, IN.
Cytologic and histologic analysis. Cytologic evaluation of human cell engraftment was performed on Wright-stained BM touch preparations. For histologic examination, samples of the sternum and lungs (in selected cases) were fixed in B-5 (BDH, Toronto, Ontario, Canada), paraffin-embedded and 2-mm sections were cut and stained with hematoxylin and eosin. Paraffin section immunohistochemistry was performed by a standard avidin-peroxidase protocol with antibodies specific for CD15 (anti-Leu-M1, Becton Dickinson), CD45 (DAKO-LCA, Dako, Mississauga, Ontario, Canada), and CD68 (KP1, Dako).
QuantiJication of human IgG and IgM levels. The levels of human IgG and IgM in the plasma of transplanted mice were analyzed by an automated particle fluorescence immunoassay procedure as previously de~cribed.'~ Briefly, affinity-purified goat-antihuman IgG and IgM (Caltag, San Francisco, CA) were covalently coated onto polystyrene beads (Baxter-Pandex, Mundelein, IL) and added to a unidirectional flow vacuum plate (Baxter-Pandex). A 1:3 serial dilution of the tested mouse plasma was mixed with the coated beads and washed. The concentrations of bound human Ig were measured by adding FITC-conjugated affinity-pure goat-antihuman IgG or IgM antibodies (Jackson Immunoresearch Laboratories, West Grove, PA); the subsequent fluorescence was read on a Baxter-Pandex Screen machine. A minimum of six duplicate dilutions were run for each sample and compared with a standard curve using purified IgG and IgM (Sigma). SCID or BALBk plasma was always included as a negative control.
RESULTS
High-level human hematopoiesis in SCID mice after cord blood transplantation. To determine whether immature
cm+ CD3+
cells capable of engrafting SCID mice were present in cord blood and to establish an experimental in vivo model for human cord blood-derived hematopoiesis, unseparated human cord blood (1 mL with 4.6 X lo6 to 19 X lo6 nucleated cells) or Ficoll-Hypaque-fractionated cells (15 to 50 X lo6) were injected into the tail vein of sublethally irradiated SCID mice. The transplanted mice were kept with or without cytokine treatment. After 4 weeks, the engraftment of human cells in the BM was analyzed by molecular methods as well as morphology. Whole cord blood and/or Ficoll-Hypaquefractionated cells from 16 of 20 donors (80%) successfully engrafted the BM of the majority of the transplanted mice. A summary of the Southern analysis of mice transplanted with cells from 12 of the donors that successfully engrafted SCID mice is shown in Fig 1. The BM from 39 of 53 mice (74%) contained greater than 10% human cells indicating a highly reproducible transplant system (Fig 1) (for a representative Southern see Fig 3B) . In addition, high levels of human cells were found in the bone marrow from mice transplanted with cells from the other 4 donors using cytology and/or immunohistology with CD45 staining.
There have been reports suggesting that significant losses of progenitor cells occur after Ficoll-Hypaque separating cord blood.' Therefore, we initially injected 1 mL of heparinized whole cord blood into irradiated SCID mice. In subsequent experiments, no significant differences were found between transplantation of unseparated whole cord blood or Ficoll-Hypaque-fractionated cells; 13 of 18 (72%) mice transplanted with whole cord blood had greater than 10% human cells detectable in the BM compared with 26 of 35 (74%) mice transplanted with Ficoll-Hypaque-fractionated cells (Fig 1) . The distribution of the human cells in engrafted SCID mice was assessed by Southern analysis of DNA extracted from the BM, lungs, liver, spleen, thymus, and kidney from mice transplanted with 5 different donors. The highest levels of human cells were consistently found in the mouse BM as shown in Fig 1. However, 1% to 10% human cells were also detected in the lungs (Fig 2 and data not shown) . In contrast, only low levels (0.1% to 1%) of human cells were present in thymus, spleen, liver, or kidney (Fig 2 and data not shown) .
Cytokine treatment is not required for human cell engraftment. After our experience with the transplantation of adult BM into SCID mice: the majority of cord blood transplanted mice received IP injections of PIXY321, a fusion protein of huIL-3 and huGM-CSF, and huMGF every other day. Interestingly, subsequent control experiments indicated that there was no difference in the level of engraftment in cord blood-transplanted mice treated with or without growth factors. This was in contrast to our previousb and concurrent experiments (data not shown) with adult BM, which always showed a clear growth factor effect. The average level of engraftment in the marrow of cord blood-transplanted mice with or without cytokine treatment was 15% (Fig 3A) as estimated by Southern analysis. The analysis included mice transplanted with six different donors. The independence from exogenous human growth factor supplements was observed whether whole blood or Ficoll-Hypaque-separated cells were transplanted into SCID mice (data not shown). As few as 5 X IO6 nucleated cells/mL whole blood were sufficient to lead to high levels (in some cases greater than 50%) of human hematopoiesis 4 weeks posttransplantation without administration of human growth factors (Fig 3B) .
Phenotypic characterization of the engrafted cells. TO characterize the human cells in the mouse BM, three-color fluorescence-activated cell sorter (FACS) analysis was performed on selected mice with a panel of antibodies directed against the human myeloid and lymphoid cell surface epitopes CD2, CD13, CD16, CD19, and CD34. The human origin of the analyzed cells was established by their staining for the panleukocyte antigen CD45 (Fig 4A) . Isotype controls and staining of a nontransplanted mouse confirmed the specificity of the staining conditions (Fig 4A) . Further analysis of the gated CD45' cells showed the presence of human cells expressing the panmyeloid surface antigen CD13 ( Fig  4A) ; however, no CD13+CD16+ mature granulocytes could be detected. Human CD45+CD19' B cells were also seen in the BM (Fig 4A) . In addition, human CD34+CD45d""CD13 early hematopoietic progenitors were found (Fig 4A) . FACS analysis of highly infiltrated lungs (Fig 4B) confirmed the presence of CD2+ and CD3' human T cells. Staining for CD4 and CD8 showed that the majority of the cells were mature CD4-CD8' T cells with a smaller proportion of mature CD4+CD8-T cells (Fig 4B) . No human cells of other lineages were found in the lungs by FACS analysis.
Touch preparations from the BM of transplanted mice were used to quickly assess human cell engraftment. In concordance with the FACS data, engrafted mice showed infiltration with early myeloid cells, mainly myeloblasts and promyelocytes (Fig 5A) . A significant percentage of the human cells differentiated into the eosinophilic lineage up to the level of mature bilobulated eosinophils. Occasionally, mature basophils and lymphoid cells were detected. In highly engrafted mice, the human cells nearly completely replaced the murine cells. Residual mouse myelopoiesis could be distinguished by the characteristic ring-shaped nuclei of the granulocytes (Fig 5B) and the fine granulation of murine eosinophils and basophils. Histologic evaluation of the sternum of engrafted mice confirmed the BM infiltration with early myeloid cells that stained positive for the human specific panleukocyte antigen CD45 (Fig 5C) and the myeloid antigen CD15 (Fig 5D) . CD68' cells of the macrophage lineage could also be detected in the BM by immunohistology. Histologic evaluation of the lungs showed perivascular and peribronchial infiltration of CD45+ human cells (Fig 5 ,  E and F) in the lungs of several mice in accordance with the results from the Southern and FACS analysis. In mouse #CB12.5, interstitial and alveolar infiltration with CD68+ human macrophages was also observed (data not shown).
The plasma of mice transplanted with cells from four donors was tested for the presence of human IgG and IgM to determine if mature B cells had engrafted the mice. Low levels of human IgG ranging from 5.7 to 233 pg/mL could be measured in 8 of 19 mice, and 2 mice also had 1 to 2 pg/mL human IgM detectable. Only highly engrafted mice (greater than 10% human cells) contained detectable levels of human Igs.
Progenitor cell activity of the transplanted human cells. To determine whether human hematopoietic progenitor cells were present, 0.5 to 2 X lo5 BM cells from engrafted mice were plated in methylcellulose cultures under conditions supporting only the growth of human cells. The BM contained an average of 200 human colonies per 1 X lo5 plated BM cells including CFU-M, CFU-GM, CFU-G, BFU-E, and multilineage CFU-GEMM (Fig 6) . No significant difference in the overall number or colony type was seen comparing mice treated with or without growth factors (data not shown). Human colonies, including CFU-GEMM, were detected in the marrow of mouse #CB8.11 14 weeks posttransplantation.
DISCUSSION
The experiments described here show that human cord blood cells can engraft sublethally irradiated SCID mice with high efficiency resulting in high levels of human multilineage hematopoiesis in the BM of transplanted mice. Mice could be engrafted with unseparated andor Ficoll-Hypaquefractionated cells showing that 1 mL of cord blood with a cell count as low as 5 X lo6 nucleated cells contained enough immature hematopoietic cells to reconstitute an SCID mouse. In some mice, more than 50% of the cells in the mouse BM were of human origin nearly completely replacing endogenous mouse myelopoiesis. Enhanced extramedullary murine hematopoiesis in the spleen appeared to compensate for the reduced BM myelopoiesis. Morphologic and For personal use only. on October 26, 2017 . by guest www.bloodjournal.org From cells had engrafted the murine BM microenvironment and were maintaining the human progenitor pool. Furthermore, FACS analysis of engrafted mice showed immature CD34+ human hematopoietic cells in the BM of transplanted mice. However, at present we cannot distinguish between the engraftment of pluripotent stem cells or committed progenitors that give rise to the different lineages. Future experiments including retroviral marking and secondary transplants will clarify the nature of the cell that engrafts the SCID mice.
Mature human T cells were frequently detected in the parabronchial and paravascular lymphoid microenvironment of the lungs from engrafted mice. This appears to reflect engraftment of mature T cells from the original donor sample and may be correlated with the high number of T cells present in cord blood. In one mouse, interstitial and alveolar infiltration with human CD68+ macrophages was observed similar to the distribution of normal CD68+ alveolar macrophages in human lungs. The presence of human T cells in the appropriate location in the murine lungs suggests that some aspects of the interaction between the human T cells and the murine microenvironment may be conserved. Surprisingly, our results show that high levels of human hematopoiesis can be achieved in cord blood-transplanted SCID mice without exogenous treatment with human growth factors. Our previous and concurrent experiments using adult BM transplanted into SCID mice have shown that immature human hematopoietic cells can home to and survive in the murine microenvironment for as long as 3 months without growth factor treatment. However, they do not proliferate and differentiate to high levels in vivo unless the mice are treated with human cytokines6 Therefore, human cord blood cells may be able to provide their own cytokines in vivo in a paracrine fashion, thus rendering themselves independent from the exogenous supply of human growth factors. Poten-VORMOOR ET AL tial sources for growth factor secretion include activated human T cells that produce IL-3 and GM-CSF24,Z5 and mature CD8+ T cells that are known to play an essential role in allogeneic engraftment independent from their potential function in overcoming residual host resistance,'6 probably by providing necessary growth factors. Alternatively, the cord blood progenitors may have a higher proliferative potential than progenitors from adult BM''.'3 andor may be more responsive to the murine microenvironment. Future studies will distinguish between the different possibilities and evaluate the role of human cord blood T cells in the engraftment process.
In conclusion, this model will be useful in gaining new insights into the biology of early human cord blood progenitors and in studying developmental changes in the human hematopoietic system by comparing hematopoietic cells from cord blood and adult BM. Such information is of particular importance as cord blood is increasingly considered as an alternative stem cell source for both autologous and allogeneic transplantation." As this model does not require manipulation of the cord blood or exogenous human growth factor treatment, it is easily applicable. In addition, cord blood cells are highly infectable with retroviral vectors"; this approach will be useful in studying gene transfer and long-term in vivo expression into human hematopoietic cells.
